Society for the Study of Addiction – Annual Conference 2017

9th – 10th November 2017
Crowne Plaza, Newcastle, UK

Confirmed sessions include:

  • Sport & exercise in addiction and recovery with personal reflections from Clarke Carlisle.
  • End of life care for people with substance problems.
  • The psychedelic renaissance in addiction treatment.
  • Pathways to amphetamine type stimulant use.

Capture.JPG


NEW for 2017: The ADDICTION DEBATE

‘This Society believes it is appropriate to expand the concept of addiction to behaviours such as internet use’

With Professor Robert West & Professor Mark Griffiths


SSA PhD Symposium 2017

New for 2017, the SSA’s PhD Symposium will be held the day before our annual Conference, in the same venue.

The SSA’s symposium for PhD students is now in its ninth year. This event aims to bring together PhD students studying addiction-related topics so they can network, present their work in a low-key, supportive environment and share their ups and downs. It welcomes full and part-time students, studying in a range of disciplines including social sciences, laboratory sciences and health services research. The day includes presentations from students at various stages in the PhD process and some close to or who have recently submitted their thesis.

There is a social event in the evening of the PhD Symposium, and throughout the day there is plenty of opportunity to talk to other delegates.

 

For more information about this event please visit: www.addiction-ssa.org/symposium

 

UKCTAS researchers awarded multi-million pound grant to tackle tobacco-related harm in Asia & Africa

UKCTAS and the Global Challenges Research Fund

UKCTAS researchers have been awarded a £3.4million grant from Research Councils UK to address tobacco-related harm in Asia and Africa. The programme will run for four years and aims to build capacity for tobacco control research in seven countries in South Asia and Africa.

GCRF-infographicLed by Professor Linda Bauld, UKCTAS Deputy Director based at the University of Stirling, this Global Challenges Research Fund grant provides an example of how UKCTAS is able to bring together members of the UK tobacco control research community to respond to an opportunity to address tobacco use in low and middle income countries.It involves six of the academic teams within the UKCTAS consortia and Cancer Research UK, one of the UKCTAS funders. CRUK is already very active in international tobacco control research.

Professor Bauld said:
Linda_Bauld_UKCTAS.png“UKCTAS has made an important contribution to informing policies and new developments to reduce smoking rates in the UK over the past decade, culminating in the very significant prevalence reductions we’ve seen in the past few years. This is testament to the links we have worked hard to forge with government, NGOs, advocacy groups, professionals and the public who have helped translate our research into practice. Our work on smokefree public places, tobacco taxation, mass media, smoking cessation & stop smoking services, electronic cigarettes & tobacco harm reduction, and our monitoring of tobacco industry activity has all fed into these changes.

Now through this GCRF programme we have a unique opportunity to help build capacity in 7 other countries, all in South Asia and Africa, adding to individual projects and links that UKCTAS members had already forged with some of these teams in recent years. A core element of our Centre has always been training and research development, from PhD through post-doctoral level, training professionals and engaging with stakeholders in the UK and Europe. Now we will be extending this through a substantial new programme of research and capacity building with a particular focus on tobacco taxation, the illicit trade and tobacco industry influence on policy. We will be working with the following list of senior researchers and their teams (below), as well as Alison Cox and her colleagues at Cancer Research UK, over the next four years. We are grateful to Research Councils UK for this opportunity.”

The UK co-applicants on the grant include: Professors John Britton and Andrew Fogarty (Nottingham), Professor Kamran Siddiqi and Dr Steve Parrot (York), Professor Jeff Collin (Edinburgh), Professor Anna Gilmore (Bath) and Professor Ann McNeill (Kings College).

International co-applicants include:

– Dr Wakgari Deressa, Addis Ababa University, Ethiopia
– Dr Muralidhar Madhav Kulkarni, Manipal University, India
– Professor Umberto Dalessandro, MRC Unit, the Gambia
– Dr Monika Arora, Public Health Foundation of India
– Dr Ellis Owusudabo, Kwame Nkrumah University of Science and Technology, Ghana
– Kellen Nyamurungi, CTCA, Makerere University, Uganda
– Dr Rumana Hugue, the ARK Foundation, Bangladesh
– Professor Corne van Walbeek, University of Cape Town, South Africa

 

Collaboration info-graphic showing the different organisations involved in the project:

GCRF-UKCTAS-Presentation-diagram

About the GCRF:

The Global Challenges Research Fund (GCRF) GCRFfullcolourResearch Councils UK Collective Fund is supporting projects in the range of £2 – 8 million over four years. It aims to build upon research knowledge in the UK, and strengthen capacity overseas, to help address challenges, informed by expressed need in the developing countries.

 

Jo Johnson, Minister for Universities and Science, said:
“From healthcare to green energy, the successful projects receiving funding today highlight the strength of the UK’s research base and our leadership in helping developing countries tackle some of the greatest global issues of our time.

“At a time when the pace of scientific discovery and innovation is quickening, we are placing science and research at the heart of our Industrial Strategy to build on our strengths and maintain our status as science powerhouse.”

More information about this grant can be seen on the UKCTAS website.

Notes to editors

· Full list of research partners:
o UK Centre for Tobacco and Alcohol Studies (UKCTAS): Universities of Stirling, Nottingham, York, Edinburgh, Kings College London and Bath.
o Cancer Research UK
o The ARK Foundation, Bangladesh
o Manipal University, India
o The Public Health Foundation of India
o The University of Cape Town, South Africa
o Makerere University, Uganda
o The MRC Unit, The Gambia
o Addis Ababa University, Ethiopia
o Kwame Nkrumah University of Science and Technology, Ghana

· More details on each of the 37 grants can be found in the Growing research capability to meet the challenges faced by developing countries brochure.

· Find out more about the Institute of Social Marketing: www.stir.ac.uk/health-sciences-sport/research/groups/social-marketing.

· Find out more about the UK Centre for Tobacco and Alcohol Studies: ukctas.net

· Find out more about Cancer Research UK’s international tobacco control programme: http://www.cancerresearchuk.org/funding-for-researchers/applying-for-funding/funding-committees/international-tobacco-advisory-group

· Find out more about tobacco consumption via the World Health Organisation: www.who.int/mediacentre/factsheets/fs339/en/

UKCTAS comment on the latest tobacco control plan for England: “Towards a smoke-free generation”

The new tobacco control plan, ‘Towards a smoke free generation’ is a welcome restatement of the government’s commitment to reduce the prevalence, and hence the burden of death and disability caused, by smoking. The recognition that harm reduction strategies can play a key role in achieving these ambitions is applauded, and puts the UK at the forefront of global tobacco policy. However, the ambition to reduce adult smoking in England from 15.5% to 12% by 2022, representing as it does a reduction of 0.5 of a percentage point per year, is modest given that smoking prevalence has fallen by 2.9 percentage points in the last three years.

Recognising reducing smoking in pregnancy as a priority, and aiming to reduce prevalence in pregnancy to 6% or less, is welcome but will not be achieved without adequate resources, improved care pathways and addressing significant gaps in training for midwives and obstetricians. The commitment to make NHS inpatient mental health settings smoke-free by 2018 is long overdue, but it is disappointing that the same strong commitment is not extended to other NHS settings.

The ambition to make stop-smoking services more available is also welcome, but like the commitments to NHS settings and for pregnancy requires funding: when public health budgets are being slashed, how will local authorities afford to increase their smoking service provision?

What matters now is delivery: Action to achieve and exceed these ambitions is the next and crucial step

PDF of the Press Release

Vaping may help explain the record fall in UK smoking rates – Press Release with comments from UKCTAS Directors

UK smoking rates showed a record annual fall between 2015 and 2016 of 1.5 percentage points, based on new statistics released today [Link]. The prevalence of smoking among people aged 18 and above in 2016 was 15.8%, the lowest on record. This dramatic reduction is also the second largest annual fall in the last 40 years.

The UK is an international leader in smoking prevention policy, having introduced high tobacco taxes, a comprehensive advertising ban, prohibited smoking in public places, taken tobacco products out of sight in shops, establishing specialist stop-smoking services and a range of other measures. These policies have caused a sustained downward trend in adult smoking prevalence over the past two decades. Over the past five years, however, the rate of decline has increased substantially, falling by 4.4 percentage points, from 20.2%, since 2011.

Today’s new figures indicate UK smoking is falling faster than would be expected from conventional tobacco control approaches. While all the policies put in place will have made a difference, the most likely explanation for the recent rapid decline is the increasing use by smokers of electronic cigarettes as a substitute for tobacco. Data released by ASH last month estimated that there are now 1.5m people in the UK who used to smoke but now instead use electronic cigarettes.

Professor John Britton said:
“Electronic cigarettes were patented in 2004 but we began to see their use in the UK from around 2010. Since then the proportion of smokers using them has risen steadily. They have rapidly become the most popular aid to stopping smoking, and are now used in more than one third of quit attempts. At first we were unsure what their impact on smoking rates would be, but today’s figures suggest that alongside established tobacco control policies, they may have significantly accelerated the downward trend in smoking”

“Overall these findings vindicate UK policy on vaping: and that doing more to encourage more smokers to make the switch could generate huge benefits in public health: especially among those groups in society where smoking remains common.”

Professor Ann McNeill said:
“Since the millennium the UK has implemented a comprehensive tobacco control strategy to encourage and support smokers to stop and to deter young people from taking up smoking. This strategy included encouraging smokers to switch from deadly cigarettes to less harmful forms of nicotine including electronic cigarettes. It is really important that the new government continues this comprehensive approach and publishes its new Tobacco Control Plan as soon as possible, particularly given the need to tackle inequalities in smoking rates across society. In times of austerity, tobacco control is a good investment, as it benefits not just smokers and their families, but services like the NHS which bear the enormous costs of treating smoking-related illnesses”

Professor Linda Bauld added:
“The UK has taken a liberal approach to vaping, supporting the use of these consumer products for smokers who choose to use them. This has been controversial, and other countries have taken a much more restrictive approach. These new prevalence figures for adults, alongside steady declines in youth smoking uptake, suggest that electronic cigarettes may turn out to be a game changer for tobacco control. However, we know that many smokers are still wary of these products and think they are as harmful as tobacco. That needs to change if the positive trend we see from today’s figures is to be maintained.”

• Adult smoking habits in the UK: 2016 – Released 15 June 2017 External Link

• Smoking statistics in England – 15 June 2017 – Latest smoking compendium report signposting to all the up-to-date smoking data. External Link

 

Download the PDF version of this Press Release

 

The Cochrane Tobacco Addiction Group’s 20th anniversary priority setting project report.

Cochrane TAG anniversary Twitter banner
The Cochrane Tobacco Addiction Group (TAG) conducts and facilitates systematic reviews and meta-analyses of the research evidence for tobacco cessation and prevention interventions. The group was founded in 1996 and in 2016 they conducted a stakeholder engagement project to celebrate the 20th anniversary of TAG and to identify future research priorities for the group and the wider tobacco control community.
 
 

The objective of the project was to:

  • Raise awareness of Cochrane TAG and what has been achieved so far.
  • Identify areas where further research is needed in the areas of tobacco control and smoking cessation.
  • Identify specific goals for Cochrane TAG
  • To explore novel ways to disseminate the findings of tobacco research, and Cochrane TAG’s findings.

The survey and workshop resulted in 183 unanswered research questions in the areas of tobacco, quitting smoking and eight priority research areas, including:

  • ‘addressing inequalities’
  • ‘treatment delivery’
  • electronic cigarettes’
  • ‘initiating quit attempts’
  • ‘young people’
  • ‘mental health and substance abuse’
  • ‘population-level interventions’
  • ‘pregnancy’

_NAS8348_web

Stakeholders who attended the workshop also discussed ways that the public health community and Cochrane TAG could act to move the field of tobacco control forward.

Through this report, Cochrane TAG want to share the identified unanswered questions with the wider tobacco research community to help them to decide the most important research to focus on in the future, and to decide the most important things to work on for Cochrane TAG.

This will involve updating existing reviews, beginning reviews on new topics, and looking in more detail at Cochrane TAG’s research methods.

Contrary to popular belief there are still many important unanswered questions in the field of tobacco control. In addition, it has been noted that many of the results of tobacco control questions are not always reaching their intended targets. Tobacco control stakeholders provide a rich source of information on how these uncertainties should be prioritised; by using this resource the likelihood that the findings of research are useful and will be implemented is much greater. The project was carried out with the hope that researchers and research funders will be able to use the priorities identified to inform their future practice, in the same way that Cochrane TAG are using them to inform new review topics, updates of reviews and methods development.

Cochrane TAG’s findings and implementation suggestions should be considered alongside the existing evidence base and clinical expertise.

 
Here is the full report of the CTAG taps project!
 
You can open the report and the appendices by clicking on the covers below:
ctag_taps_final_reportctag_taps_final_report_appendices
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Discussing the future of tobacco addiction research with the Cochrane Tobacco Addiction Group:

The CTAG taps project ran from January-December 2016. Activities carried out from April 2016-December 2016 were funded by the NIHR School for Primary Care Research (SPCR)

10th annual Global Research Awards for Nicotine Dependence (GRAND) program

GRAND is a Pfizer-supported independently reviewed competitive grants program awarding individual grants of up to $200,000 from a total fund in 2017 of $1 million to support projects which directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Of 486 applications received since 2008, 62 grants have been awarded.

Pfizer has called for Clinical research proposals that aim to increase the understanding of the mechanisms of tobacco and nicotine dependence and its treatment. The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.

Each proposal should fall into one of the following areas:

  • Human laboratory (e.g., pharmacokinetics, pharmacodynamics, cravings, withdrawal);
  • Pharmacotherapy of smoking cessation and relapse, and / or its interaction with behavioral support;
  • Characterization of subtypes of smokers; suitability for appropriate interventions.

Research projects should aim to provide information that could directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Examples could include:

  • Observational or interventional studies of pharmacotherapy
  • Optimization of the use of currently available medication
  • Effectiveness of pharmacotherapy in real-life settings
  • Development or use of new medications for cessation or harm reduction
  • Specifically designed pharmacotherapy in subtypes of tobacco/nicotine users
  • Use of existing databases to inform the clinical use of pharmacotherapy
  • Policy interventions to increase use of pharmacotherapy.

The intent of the program is to fund at least 6 awards of between $50,000 and $200,000 in value, totaling $1.2 million. The awards are open to all investigators and they would strongly encourage applications from junior investigators.

Applications will be formally assessed by, and only by, the GRAND Review Committee, an independent committee comprising internationally prominent researchers in the field. The final responsibility for selection of Awardees rests with the Co-Chairs of the Review Committee, John Hughes and Karl Fagerstrom. The whole process is completely independent of Pfizer, including the final selection of Awardees.

GRAND is open to all investigators from around the world holding an MD, a PhD, or equivalent.

Application deadline: July 3, 2017

To apply for the grant and for more information on the application process click here!

 

New evidence finds standardised cigarette packaging may reduce the number of people who smoke as UK legislation bans the use of branding on all cigarette packets from May 2017.

A Cochrane Review published today finds standardised tobacco packaging may lead to a reduction in smoking prevalence and reduces the appeal of tobacco.

According to the World Health Organisation, tobacco use kills more people worldwide than any other preventable cause of death. Global health experts believe the best way to reduce tobacco use is by stopping people starting to use tobacco and encouraging and helping existing users to stop.

plain-packs-620-x-348-heroThe introduction of standardised (or ‘plain’) packaging was recommended by the World Health Organisation, Framework Convention on Tobacco Control (WHO FCTC) guidelines. This recommendation was based on evidence around tobacco promotion in general and studies which examined the impact of changes in packaging on knowledge, attitudes, beliefs and behaviour. Standardised tobacco packaging places restrictions on the appearance of tobacco packs so that there is a uniform colour (and in some cases shape) with no logos or branding apart from health warnings and other government-mandated information, and the brand name appears in a prescribed uniform font, colour and size.

From next month, UK legislation on standardised packaging for all tobacco packs comes into full effect.

Australia was the first country in the world to implement standardised packaging of tobacco products.  The laws, which took full effect there in December 2012, also required enlarged pictorial health warnings.

A team of Cochrane researchers from the UK and Canada have summarised results from studies that examine the impact of standardised packaging on tobacco attitudes and behaviour. They have today published their findings in the Cochrane Library.

Continue reading